BioNTech Buys German Manufacturing Site From Novartis for COVID-19 Vaccine

Germany-based BioNTech has announced that it will buy a Novartis manufacturing facility to quickly expand its COVID-19 vaccine production capacity.

The Manburg, Germany, facility will expand BioNTech’s production capacity for BNT162b2 by up to 750 million doses annually. The company said it expects to be able to produce up to 250 million doses by the first half of 2021.

Co-developers Pfizer and BioNTech are preparing for a global roll-out of the vaccine as soon as it receives an Emergency Use Authorization or approval from regulators.